MCAS Is Not a Diagnosis of Exclusion — It Has Real Criteria
Mast cells are immune sentinels stationed throughout the skin, gut lining, airways, and blood vessel walls. When they degranulate, they release histamine, tryptase, prostaglandins, and dozens of other mediators — producing symptoms that can look like allergy, IBS, migraine, or dysautonomia depending on which tissues are affected during a given episode. Mast cell activation syndrome describes a pattern where this degranulation happens too easily and too often, without the clear external trigger (specific allergen, parasite, malignancy) that would point to a more defined diagnosis.
The condition has historically been over-diagnosed based on symptom pattern-matching alone, which is why the field converged on the Vienna consensus criteria (Valent et al., 2019): symptoms across at least two organ systems, occurring episodically; a tryptase rise of 20% + 2 ng/mL over the person's own baseline captured during a flare; and objective improvement on mast-cell-targeted medication. A person who "feels better on antihistamines" but has never had a captured tryptase rise does not meet the criteria for MCAS by this definition — though they may still benefit from the same management approach.
MCAS vs. Histamine Intolerance vs. IgE Allergy
These three conditions are frequently conflated because they share overlapping symptoms — flushing, hives, GI distress, headache — but the underlying mechanism and testing differ substantially:
| Feature | MCAS | Histamine Intolerance | IgE-Mediated Allergy |
|---|---|---|---|
| Mechanism | Mast cells degranulate inappropriately, releasing histamine plus many other mediators | Normal mast cell function; impaired histamine degradation (DAO/HNMT) lets dietary histamine accumulate | IgE cross-linking on mast cells/basophils by a specific allergen |
| Trigger predictability | Often unpredictable — heat, stress, exercise, unrelated foods, medications, even pressure can trigger a flare | Dose-dependent on dietary histamine load — predictable threshold effect | Reproducible with the specific allergen |
| Serum tryptase | Elevated relative to baseline during flares (per Vienna criteria); baseline itself may be normal | Normal | Normal at baseline; can rise acutely during anaphylaxis |
| Serum IgE | Normal/negative | Normal/negative | Elevated total and allergen-specific IgE |
| Diagnostic test | Event-related tryptase rise (20% + 2 ng/mL over baseline) plus symptom/response criteria | Symptom diary + elimination/reintroduction; DAO activity assay in some cases | Skin prick or specific IgE blood testing |
The Gut Microbiome and SIBO Connection
Two recent lines of research point to a real, measurable gut-microbiome dimension in mast cell disease. First, a prospective study by Weinstock and colleagues (2020) found that 30.9% of MCAS patients tested positive for small intestinal bacterial overgrowth (SIBO) on breath testing, compared with 10.0% of healthy controls — roughly triple the rate. The proposed mechanism runs both directions: bacterial overgrowth in the small intestine produces metabolites and bacterial components (including lipopolysaccharide) that can directly provoke mast cell degranulation, while mast cell mediators released into the gut lining can in turn slow motility and alter the local environment in ways that favor bacterial overgrowth — a plausible self-reinforcing loop.
Second, a 2025 study in the Journal of Allergy and Clinical Immunology: Global analyzed stool samples from 22 patients with systemic mastocytosis (a related mast cell disorder) against 9 healthy controls and found measurable dysbiosis: a shift in the Firmicutes-to-Bacteroidetes ratio, altered predicted short-chain fatty acid metabolism pathways, and signals of increased microbial virulence-factor genes alongside decreased bacterial defense-mechanism genes. The same study found that specific dietary components tracked with symptom severity, quality-of-life scores, and markers of mast cell activation — evidence that diet and the microbiome are not incidental to mast cell disease but mechanistically linked to it.
This is a meaningfully different picture from the standalone "avoid histamine-containing foods" advice that circulates for mast cell conditions. For a subset of MCAS patients, especially those with prominent GI symptoms, addressing SIBO directly — rather than only restricting diet — may address a genuine upstream driver.
Getting an Actual MCAS Diagnosis (Not a Guess)
- Capture tryptase during a flare, not after: a single resting tryptase level is close to meaningless for MCAS. The Vienna criteria require a tryptase draw during or within a few hours of a symptomatic episode, compared against a separate baseline draw taken while well — looking for a rise of 20% above baseline plus 2 ng/mL.
- Rule out mimics first: IgE allergy testing (skin prick or specific IgE) and a histamine-intolerance elimination trial should be considered before settling on an MCAS diagnosis, since both are more common and more straightforwardly treated.
- Screen for SIBO if GI symptoms are prominent: given the roughly threefold higher SIBO prevalence in MCAS patients (Weinstock 2020), a lactulose or glucose breath test is a reasonable step — especially if symptoms persist despite antihistamine therapy.
- Standard first-line management: combined H1 antihistamine (e.g. a non-sedating option like cetirizine or fexofenadine) plus an H2 blocker (e.g. famotidine), escalating to a mast cell stabilizer (cromolyn sodium, ketotifen) if symptoms are not controlled — decisions that should be made with a physician familiar with mast cell disease, as dosing in MCAS management often runs higher than standard allergy dosing.
- Track triggers, don't just restrict foods blindly: because MCAS triggers extend well beyond diet (heat, friction, exercise, fragrance, certain medications), a broad symptom-and-trigger log is usually more useful than an immediate strict elimination diet.
Quercetin and vitamin C are commonly used as adjunctive mast cell stabilizers alongside — not instead of — physician-directed antihistamine/H2-blocker therapy. Discuss any supplement with your prescriber if you're on other mast cell medications, since interactions and dosing thresholds vary by individual.